Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11

Not Applicable

Completed

• Conditions: Opioid-Related Disorders; Substance-Related Disorders
• Interventions: Other: Placebo; Drug: 0.3 % Sevoflurane; Drug: 0.6% Sevoflurane; Drug: 15 % Nitrous oxide; Drug: 30% Nitrous oxide

• Registration Number: NCT00000259
• Lead Sponsor: University of Chicago

Brief Summary

The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. Comparisons between nitrous oxide, opiates, and benzodiazepine antagonists will be made. To examine sevoflurane versus isoflurane inhalation at subanesthetic concentrations on mood, pain, and psychomotor performance.

Detailed Description

Not available

Study Timeline

• Study Start: 1996-08
• Primary Completion: 1997-11
• Study Completion: 1997-11
• Study First Submitted: 1999-09-20
• Study First Submitted QC: 1999-09-20
• Study First Posted: 1999-09-21
• Status Verified: 2015-05
• Last Update Submitted: 2015-05-26
• Last Update Posted: 2015-05-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Subject inhales no drug (100% oxygen)
0.3% sevoflurane	0.3 % Sevoflurane	-
0.6% sevoflurane	0.6% Sevoflurane	-
15% Nitrous oxide	15 % Nitrous oxide	-
30% Nitrous oxide	30% Nitrous oxide	-

Primary Outcome Measures

Name	Time	Method
Pain intensity	30 min of inhalation	Subjects underwent a 3 min cold immersion test at 30 min of inhalation and then provided response to pain intensity questionnaire
Psychomotor performance	Baseline, 5 min of inhalation; 5, 30, 60 minutes recovery	Subjects underwent psychomotor testing at baseline, during inhalation, and during recovery post inhalation
Cognitive performance	Baseline, every 5 min during inhalation, 5, 30, & 60 min during recovery	Subject underwent memory, sedation, visual analog, and drug effects testing

Trial Locations

Locations (1)

University of Chicago, Anesthesia & Critical Care; 🇺🇸 Chicago, Illinois, United States